Inquire About a Product| Product: | Sunitinib malate | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Catalog Number: | 18279 | ||||||||
| CAS Number: | 341031-54-7 | ||||||||
| Pricing: |
|
||||||||
| Formula: | C22H27FN4O2 • C4H6O5 | ||||||||
| Chemical Purity: | >98% | ||||||||
| Molecular Weight: | 532.57 | ||||||||
| Structure: |
|
||||||||
| Appearance: | Solid | ||||||||
| Category: | Anti-cancer compounds | ||||||||
| Stability: | Stable under recommended storage conditions. | ||||||||
| Storage: |
Keep container tightly closed in a dry and well-ventilated place |
||||||||
| Transportation: |
Non-hazardous for transport |
||||||||
| Literature References: |
Hersey P., et al., Small molecules and targeted therapies in distant metastatic disease. Ann. Oncol. 6, 35-40, (2009); Thomposon Coon JS., et al., Stein K., Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. Br. J. Cancer 101, 238-243, (2009); Gan HK., et al., Sunitinib in solid tumors. Expert Opin. Investig. Drugs 18, 821-834, (2009); Merck 14,9000 |
||||||||
| MSDS: | |||||||||
| Description: |
Sunitinib malate is a receptor tyrosine kinase inhibitor, which targets VEGF-R1, VEGF-R2, VEGF-R3, PDGF-Rα, PDGF-Rβ, KIT, FLT3, CSF-1R, and RET. Sunitinib malate is an anticancer drug. |